Exploring the Future of Innovative Drug R&D Commercialization: Zhangjiang Tech Investment and Legend Capital Co-host Platform Forum at VB100 Future Healthcare 100 Summit 2023
Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheavals and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic deployments outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “stand firm despite countless trials,” and embodying the spirit to “press forward amid greater difficulties,” can innovators in the healthcare sector reinforce their confidence through decisive action, thereby delivering a commendable response to the era’s call for high-quality development in healthcare.
The 7th Future Healthcare Top 100 Conference, themed “No Boundaries Between East and West,” is organized byVCBeat VB100, VCBeatHosted by,Shanghai Zhangjiang GroupStrategic collaboration, integrating “cutting-edge academic research expertise, comprehensive industry insights, and keen awareness of capital market trends,” atMay 5–7, 2023, at the Shanghai Zhangjiang Science HallHeld to explore the innovative future of the broader health industry alongside peers, embarking on a new journey in medical innovation.
Having been held for six editions, the conference has become China’s largest and most information-rich ecosystem summit integrating industry and capital within the medical and health innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the technological future, and focusing on venture capital interaction,” it sets the trend for innovation and investment in China’s medical and health field. The 7th Future Healthcare 100 Conference in 2023 will feature three major summits, over 20 thematic forums in specialized fields, the release of the Future Healthcare 100 series rankings and awards, more than ten series reports, and seven concurrent networking events. It will bring together a diverse array of guests and attendees, including government agencies, academicians and scientists, research and clinical experts, Fortune 500/listed companies, top-tier investment institutions/securities firms, and innovative medical and healthcare enterprises. Through this gathering of minds, the conference aims to provide insights to the industry and usher in a new future.
“Only dare to be brave, only strive to bloom, ask not of west or east” makes a powerful arrival!
Zhangjiang Sci-Tech Investment and Legend Capital Join Forces to Explore the Secrets and Opportunities in Translating Innovative Drug Research Achievements
Focusing on the healthcare sector, Legend Capital has strategically invested in four key sub-sectors: biopharmaceuticals, healthcare informatics, medical devices, and healthcare services, achieving comprehensive coverage across the entire industry chain. The firm’s portfolio is predominantly composed of biopharmaceutical companies, including Harbour Biomed, D3 Bio, XiHua Testing, MicuRx Pharmaceuticals, BaseCura, and Haihe Biopharma, most of which are engaged in the research, development, and services of innovative drugs.
Meanwhile, Zhangjiang Sci-Tech Investment has consistently adhered to its core focus on “hard tech” investment, driving innovation through technological investment and empowering innovative enterprises to “accelerate their growth.” In the life and health sector, it has invested in more than 50 projects to date, witnessing over 40 portfolio companies list on domestic and overseas capital markets. Among these, eight companies rang the listing bell in 2022, including Obio Technology, RemeGen, InnoCare Pharma, and OPM Biotech. Additionally, Zhangjiang Sci-Tech Investment has made cumulative investments in multiple top-tier frontier funds in the life and health industry, further leveraging the “relay” of capital to help innovative enterprises showcase Zhangjiang’s innovation strength across China and globally.
From May 5 to 7, 2023, the 7th Future Healthcare Top 100 Conference will present a comprehensive exchange event for the healthcare industry, integrating “cutting-edge academic and research insights, holistic industry perspectives, and keen capital market trends.”VCBeat VB100CombinedZhangjiang Sci-Tech Investment, Legend Capital, co-hosted byForum on the Translation of Scientific Research Achievements for Innovative Drugs, comprehensively explore the ecological development trends in the translation of innovative drug research achievements from multiple perspectives, promote interdisciplinary integration and development, and foster collaboration across upstream and downstream industries.
Zhangjiang Sci-Tech Investment and Legend Capital Invite You to the Forum on the Innovation Drug R&D Achievement Transformation Platform
Conference Time:
May 5–7, 2023
Forum on the Platform for Translating Innovative Drug Research Achievements:
May 5, 2023
Venue:
Shanghai Zhangjiang Science Hall (No. 1393 Haike Road, Pudong New Area, Shanghai)
Conference Registration:
(General Conference Pass: Enjoy Access to 30+ Forums)
About Zhangjiang Sci-Tech Investment
Shanghai Zhangjiang Technology Venture Capital Co., Ltd. (hereinafter referred to as “Zhangjiang Ke Tou”) was established in October 2004 as a wholly-owned subsidiary of Shanghai Zhangjiang (Group) Co., Ltd. At the end of 2014, Zhangjiang Group integrated resources and, with Zhangjiang Ke Tou as the core entity, built a sci-tech innovation service platform featuring combined functions of investment, lending, incubation, and education. Member units include Zhangjiang Science & Technology Loan Company, Zhangjiang Incubator, Zhangjiang Pharma Valley Platform, and Zhangjiang Innovation Academy.
Zhangjiang Sci-Tech Investment takes industrial promotion as its core value, deeply cultivating the “Zhangjiang” area. It has long focused on technology investment in hard-tech and emerging industries such as life health, digital information, and artificial intelligence. By leveraging the role of state-owned capital as a ballast and stabilizer, it also mobilizes social capital to provide financial support for technological innovation enterprises. Relying on the overall resource advantages of Zhangjiang to accelerate empowerment, it gives full play to the synergistic effects of investment, lending, incubation, and learning. By linking specialized industrial parks, open innovation centers, and external innovation cultivation institutions, it builds an ecosystem for the integrated development of large, medium, and small enterprises, committed to achieving full-lifecycle industrial promotion from “angel investment – incubators (open innovation centers) – specialized investment funds – specialized park carriers – IPO listing.”
By leveraging the combined empowerment of capital and ecosystem, we have accelerated the development of technology innovation enterprises. A large cohort of dynamic new players has already emerged from Zhangjiang Sci-Tech Investment’s ecosystem, with over 100 ecosystem companies listing on domestic and overseas capital markets, including more than 40 on the STAR Market.
About Legend Capital
Legend Capital was established in April 2001 and is a leading fund management company in China specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, Legend Capital drives corporate innovation and growth, consistently delivering strong investment returns across multiple sectors while promoting industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.
Legend Capital maintains a deep focus on investments in the healthcare sector, systematically deploying capital across the broader health industry. In this field, it has backed several leading companies in niche segments that are listed on the A-share and Hong Kong stock markets, including Pharmaron (300759.SZ)(03759.HK), WuXi AppTec (603259.SH)(02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ).
